Clinical trials: Age-Related Maculopathy
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish…
- Trial name
- NCT01782352
- Testing
- Omega-3 fatty acids (fish oil), Vitamin D3
- Where
- United States
- Volunteers
- 25,871 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for they eye to adjust to low light.
- Trial name
- NCT03478878
- Testing
- Vitamin A Palmitate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
An Extension to Study MD7108240
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
- Trial name
- NCT00733304
- Testing
- Pazopanib
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Macular Degeneration
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult…
- Trial name
- NCT00220805
- Testing
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Grifols Therapeutics LLC
Age-Related Macular Degeneration, Macular Degeneration
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related…
- Trial name
- ATLAS (NCT01773954)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MidAtlantic Retina
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal…
- Trial name
- NCT00284089
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 88 people
- Sponsor
- Novartis
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age Related Macular Degeneration
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations…
- Trial name
- NCT03930641
- Testing
- RTH258
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Age-Related Macular Degeneration
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
- Trial name
- COMPASS (NCT01402544)
- Testing
- ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Wet Age-related Macular Degeneration
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).
- Trial name
- NCT03558074
- Testing
- ALK4290
- Where
- 5 sites in Hungary
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Age-related Macular Degeneration
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of the safety of AGN-150998 administered as a single intravitreal injection to patients with advanced exudative Age-related Macular…
- Trial name
- NCT01397409
- Testing
- AGN-150998, ranibizumab
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Allergan
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration
SD-OCT Angiography
The objective of this study is to image retinal vascular alterations in patients with retinal disease using the AngioVue OCT-A system and understand the information these images provide.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT02510885
- Testing
- AngioVue SD-OCT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University